ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research

ChromaDex R&D program continues to pioneer NAD+ and Niagen® research and inks over 200 external research collaborations

LOS ANGELES–(BUSINESS WIRE)–$CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External Research Program (CERP™). The program provides Niagen® (nicotinamide riboside) ingredient and placebos at no cost as well as technical expertise and intellectual property support to leading research institutions and universities around the world, advancing the evidence and understanding of the health impact of increasing NAD+ levels through NR supplementation. The program has resulted in 60 publications to date, including 10 published human trials supporting the safety and efficacy of Niagen®.

“We are proud to be at the forefront of NAD+ research with a network of researchers from leading institutions and universities around the globe,” says Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. “Our partnerships through CERP™ have created a breadth of clinical and preclinical research backing the safety and efficacy of Niagen® with ongoing research across a variety of areas including cardiovascular, liver, muscle, immune and cognitive health.”

Supporting cellular defense and repair by boosting NAD+ levels is important for healthy aging. NAD+ levels decline with age as well as physiological stressors including intense exercise, lack of healthy sleep cycles, and stress on the immune system.

ChromaDex, the exclusive licensee of Dr. Charles Brenner’s patented NR, has since invested over $35 million in investigating, manufacturing and offering NR in the form of Niagen® and has secured more than 20 patents. ChromaDex has demonstrated the safety and efficacy of Niagen® in ten published human trials (and over 20 ongoing studies) and has achieved government regulatory acceptance in the United States, Canada, the European Union, and Australia.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether the CERP™ program advances the evidence and understanding of the health impact of increasing NAD+ levels through NR supplementation and whether it has created a breadth of clinical and preclinical research backing the safety and efficacy of Niagen®. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts

ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com